BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

9 Months Ended

Jun. 30, 2022

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Three Month Period Ended:
	June 30,		June 30,
	2022		2021
Research and development services (over-time)	$	152,732	$	197,812
Clinical laboratory testing services (point-in-time)		2,506,976		695,213
Clinical laboratory testing services (over-time)		1,386,834		131,400
Product and authentication services (point-in-time):
Supply chain		43,243		23,947
Asset marking		127,075		113,721
Diagnostic test kits and supplies		79,511		538,227
Total	$	4,296,371	$	1,700,320

	Nine Month Period Ended:
	June 30,		June 30,
	2022		2021
Research and development services (over-time)	$	472,539	$	586,285
Clinical laboratory testing services (point-in-time)		8,712,565		2,698,463
Clinical laboratory testing services (over-time)		3,871,609		455,800
Product and authentication services (point-in-time):
Supply chain		570,252		123,947
Asset marking		380,039		386,160
Diagnostic test kits and supplies		602,356		1,737,348
Total	$	14,609,360	$	5,988,003

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		June 30,		$
	Balance sheet classification	2021		2022		change
Contract liabilities	Deferred revenue	$	281,000	$	757,264	$	476,264

Schedule of anti-dilutive securities not included computation of net loss per share

	2022	2021
Warrants	2,239,963	745,268
Stock options	1,063,143	452,485
Total	3,303,106	1,197,753